PHARMACOLOGY

Daniel SCOTCHER

SITE

Clin Pharmacol Ther. 2022;In press. Coproporphyrin I as an endogenous biomarker to detect reduced OATP1B activity and shift in elimination route in chronic kidney disease. Takita H, Scotcher D, Chu X, Yee KL, Ogungbenro K, Galetin A. PubMed

Clin Pharmacol Ther. 2022;In press. Effect of chronic kidney disease on the renal secretion via Organic Anion Transporters 1/3: Implications for Physiologically-Based Pharmacokinetic modeling and dose adjustment. Tan SPF, Scotcher D, Rostami-Hodjegan A, Galetin A. PubMed

AAPS J. 2021;24:13. PBPK simulation-based evaluation of Ganciclovir crystalluria risk factors: Effect of renal impairment, old age, and low fluid intake. Scotcher D, Galetin A. PubMed

Clin Pharmacol Ther. 2021;110:1389-1400. Quantitative proteomic map of enzymes and transporters in the human kidney: Stepping closer to mechanistic kidney models to define local kinetics. Al-Majdoub ZM, Scotcher D, Achour B, Barber J, Galetin A, Rostami-Hodjegan A. PubMed

Mol Pharm. 2021;18:2997-3009. Physiologically based pharmacokinetic modeling of transporter-mediated hepatic disposition of imaging biomarker Gadoxetate in rats. Scotcher D, Melillo N, Tadimalla S, Darwich AS, Ziemian S, Ogungbenro K, Schütz G, Sourbron S, Galetin A. PubMed

Drug Metab Dispos2021;49:563-571. Hepatic scaling factors for in vitro-in vivo extrapolation (IVIVE) of metabolic drug clearance in patients with colorectal cancer with liver metastasis. Vasilogianni AM, Achour B, Scotcher D, Peters SA, Al-Majdoub ZM, Barber J, Rostami-Hodjegan A. PubMed

Clin Pharmacokinet. 2021;60:1187-1199. Clinical investigation on endogenous biomarkers to predict strong OAT-mediated drug-drug interactions. Willemin ME, Van Der Made TK, Pijpers I, Dillen L, Kunze A, Jonkers S, Steemans K, Tuytelaars A, Jacobs F, Monshouwer M, Scotcher D, Rostami-Hodjegan A, Galetin A, Snoeys J. PubMed

CPT Pharmacometrics Syst Pharmacol. 2020;9:695-706. Physiologically-based pharmacokinetic modelling of Creatinine-drug interactions in the chronic kidney disease population. Takita H, Scotcher D, Chinnadurai R, Kalra PA, Galetin A. PubMed

Drug Metab Dispos. 2020;48:1271-1282. Scaling factors for clearance in adult liver cirrhosis. El-Khateeb E, Achour B, Scotcher D, Al-Majdoub ZM, Athwal V, Barber J, Rostami-Hodjegan A. PubMed

CPT Pharmacometrics Syst Pharmacol. 2020;9:310-321. A novel physiologically based model of Creatinine renal disposition to integrate current Kknowledge of systems parameters and clinical observations. Scotcher D, Arya V, Yang X, Zhao P, Zhang L, Huang SM, Rostami-Hodjegan A, Galetin A. PubMed

CPT Pharmacometrics Syst Pharmacol. 2020;9:282-293. Mechanistic models as framework for understanding biomarker disposition: Prediction of Creatinine-drug interactions. Scotcher D, Arya V, Yang X, Zhao P, Zhang L, Huang SM, Rostami-Hodjegan A, Galetin A. PubMed

Mol Pharm. 2019;16:4551-4562. Quantitative translation of microfluidic transporter in vitro data to in vivo reveals impaired albumin-facilitated Indoxyl Sulfate secretion in chronic kidney disease. van der Made TK, Fedecostante M, Scotcher D, Rostami-Hodjegan A, Sastre Toraño J, Middel I, Koster AS, Gerritsen KG, Jankowski V, Jankowski J, Hoenderop JGJ, Masereeuw R, Galetin A. PubMed

J Pharmacol Exp Ther. 2019;368:157-168. Towards further verification of physiologically-based kidney models: Predictability of the effects of urine-flow and urine-pH on renal clearance. Matsuzaki T, Scotcher D, Darwich AS, Galetin A, Rostami-Hodjegan A. PubMed

Drug Metab Dispos. 2017;45:556-568. Microsomal and cytosolic scaling factors in dog and human kidney cortex and application for in vitro-in vivo extrapolation of renal metabolic clearance. Scotcher D, Billington S, Brown J, Jones CR, Brown CDA, Rostami-Hodjegan A, Galetin A. PubMed

J Pharmacol Exp Ther. 2017;360:484-495. Delineating the role of various factors in renal disposition of Digoxin through application of physiologically based kidney model to renal impairment populations. Scotcher D, Jones CR, Galetin A, Rostami-Hodjegan A. PubMed

AAPS J. 2016;18:1082-1094.  Key to opening kidney for in vitro-in vivo extrapolation entrance in health and disease: Part II: Mechanistic models and in vitro-in vivo extrapolation. Scotcher D, Jones C, Posada M, Galetin A, Rostami-Hodjegan A. PubMed

Eur J Pharm Sci. 2016;94:59-71. Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. Scotcher D, Jones C, Rostami-Hodjegan A, Galetin A. PubMed